Combined p53‐related genetic variants together with HPV infection increase oral cancer risk
Authors:
Open Access
- 2 November 2011
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 131 (3) , E251-E258
Abstract
To explore the role of polymorphisms of p53‐related genes in etiology of oral cancer, we investigated joint effects of seven putatively functional polymorphisms of p53 (codon 72 Arg/Pro), p73 (4/14 GC/AT), murine double minute 2 gene (MDM2; A2164G and T2580G) and MDM4 (rs11801299 G > A, rs10900598 G > T and rs1380576 C > G) on risk of human papillomavirus (HPV)16‐associated oral cancer in a case–control study with 325 cases and 335 cancer‐free controls. We found that HPV16 seropositivity alone was associated with an increased risk of oral cancer [adjusted odds ratio (OR), 3.1; 95% confidence interval (CI), 2.1–4.6]. After combining genotypes of seven polymorphisms and using the low‐risk group (0–3 combined risk genotypes) and HPV16 seronegativity as the reference group, the medium‐risk (4 combined risk genotypes) and high‐risk groups (5–7 combined risk genotypes) and HPV16 seronegativity were associated with only an OR of 1.6 (95% CI, 1.1–2.5) and 1.2 (95% CI, 0.7–1.9) for oral cancer risk, respectively, whereas the low‐risk, medium‐risk and high‐risk groups and HPV16 seropositivity were significantly associated with a higher OR of 2.1 (95% CI, 1.2–3.6), 4.0 (95% CI, 1.8–9.1) and 19.1 (95% CI, 5.7–64.2), respectively. Notably, such effect modification by these combined risk genotypes was particularly pronounced in young subjects (aged < 50 years), never smokers and patients with oropharyngeal cancer. Taken together, these findings suggest that the combined risk genotypes of p53‐related genes may modify risk of HPV16‐associated oral cancer, especially in young patients, never‐smokers and patients with oropharyngeal cancer. Larger studies are needed to validate our findings.Keywords
This publication has 41 references indexed in Scilit:
- TP73 alterations in cervical carcinomaCancer Genetics and Cytogenetics, 2004
- Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in JapaneseCancer Letters, 2004
- Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification targetInternational Journal of Cancer, 2003
- MdmX Is a RING Finger Ubiquitin Ligase Capable of Synergistically Enhancing Mdm2 UbiquitinationJournal of Biological Chemistry, 2002
- Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human CancersCell, 1997
- Evaluation of Seroreactivity to Human Papillomavirus Type 16 Virus-like Particles in an Incident Case-Control Study of Cervical NeoplasiaThe Journal of Infectious Diseases, 1995
- A Virus-Like Particle Enzyme-Linked Immunosorbent Assay Detects Serum Antibodies in a Majority of Women Infected With Human Papillomavirus Type 16JNCI: Journal of the National Cancer Institute, 1994
- Serologic response in human papillomavirus‐associated invasive cervical cancerInternational Journal of Cancer, 1993
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992
- The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53Cell, 1990